The Gut Barrier Protocol — BPC-157 + KPV & Advanced Additions
A comprehensive gut barrier restoration protocol with two tiers. Core Protocol: BPC-157 (mucosal regeneration via VEGF) and KPV (inflammation suppression via MC1R/NF-kB). Advanced Additions: Colostrum (growth factor-mediated regeneration), Sodium Butyrate (colonocyte energy and epigenetic modulation), and Zinc (tight junction cofactor). Designed for leaky gut, IBD, post-antibiotic dysbiosis, and SIBO recovery.
Daily Schedule
Timing and dosage for each step
08:00 AM
500 mcg
Core Protocol. Oral BPC-157 capsule with breakfast. For gut-targeted effects, oral route concentrates peptide in GI tract. Take with food.
08:00 AM
2 mg
Core Protocol. KPV capsule with breakfast. Enteric-coated if available. Oral route preferred for gut-localised anti-inflammatory effect.
06:00 PM
06:00 PM
Morning
4000 mg
Advanced Addition. Colostrum 2–4g oral powder/capsule with morning BPC-157. Provides growth factors (IGF-1, EGF, TGF-beta) for mucosal cell proliferation and tight junction protein expression.
With meals
600 mg
Advanced Addition. Sodium Butyrate 600mg enteric-coated with meals. Primary energy substrate for colonocytes and HDAC inhibitor — shifts gene expression toward anti-inflammatory patterns.
With meals
30 mg
Advanced Addition. Zinc 15–30mg daily with meals. Cofactor for tight junction protein synthesis — directly upregulates occludin and ZO-1 expression.
Protocol Overview
The gut barrier is the interface between the external world and your bloodstream. When compromised — by antibiotics, NSAIDs, alcohol, stress, or autoimmune activity — increased intestinal permeability drives systemic inflammation, food sensitivities, and impaired nutrient absorption.
This protocol uses a two-tier approach: a core peptide protocol for structural repair and inflammation suppression, plus advanced additions for growth factor support, epigenetic modulation, and cofactor optimisation.
Core Protocol — BPC-157 + KPV
BPC-157 (Body Protection Compound) promotes healing via VEGF upregulation and growth factor signalling — rebuilding the mucosal lining and improving local blood supply. It upregulates VEGF for angiogenesis, activates FAK-paxillin for directed fibroblast migration, and sensitises GH receptors at the mucosal surface.
KPV (Lys-Pro-Val) suppresses gut inflammation via MC1R activation — reducing NF-kB, lowering TNF-alpha and IL-1beta, and polarising macrophages toward a repair phenotype. KPV's oral stability makes it uniquely suited for gut delivery without injection.
Healing cannot occur in a high-inflammation environment. KPV suppresses the inflammatory milieu; BPC-157 rebuilds the mucosal architecture.
Advanced Additions
Once the Core Protocol is established (4+ weeks), add these three compounds for comprehensive gut barrier restoration.
Colostrum provides growth factors (IGF-1, EGF, TGF-beta) that drive mucosal cell proliferation and tight junction protein expression. The immunoglobulin fraction (IgA) supports mucosal immunity without systemic immunosuppression. 2–4g/day oral powder/capsule.
Sodium Butyrate is the primary energy substrate for colonocytes and a potent HDAC inhibitor. HDAC inhibition shifts gene expression toward anti-inflammatory, tight junction-upregulating patterns. Enteric-coated forms ensure colonic delivery. 600mg/day with meals.
Zinc is a cofactor for tight junction protein synthesis and directly upregulates occludin and ZO-1 expression. Zinc deficiency is common in gut-compromised individuals. 15–30mg/day with meals.
Dosing Summary
| Compound | Dose | Timing | Route | Tier |
|---|---|---|---|---|
| BPC-157 | 0.5mg | 08:00 AM + 06:00 PM | Oral capsule | Core |
| KPV | 2mg | 08:00 AM + 06:00 PM | Oral capsule (enteric-coated) | Core |
| Colostrum | 2–4g/day | Morning with BPC-157 | Oral powder/capsule | Advanced |
| Sodium Butyrate | 600mg/day | With meals | Oral, enteric-coated | Advanced |
| Zinc | 15–30mg/day | With meals | Oral | Advanced |
Who This Protocol Is For
- Leaky gut / intestinal hyperpermeability
- Inflammatory bowel disease (Crohn's, ulcerative colitis) — adjunctive to medical treatment
- Post-antibiotic dysbiosis and gut damage
- SIBO (Small Intestinal Bacterial Overgrowth) recovery
- NSAID or alcohol-related gut damage
- Food sensitivity driven by gut permeability
Oral vs. Subcutaneous Administration
For gut-targeted effects, oral administration is preferred. Oral BPC-157 and KPV concentrate the peptides in the gastrointestinal tract rather than distributing systemically. Use enteric-coated capsules where available to improve small intestinal delivery.
Subcutaneous BPC-157 may be added for systemic repair effects in severe cases.
Protocol Duration
Acute phase (Weeks 1–4): Core Protocol only — BPC-157 + KPV twice daily Phase 2 (Weeks 5–12): Add Advanced Additions (Colostrum, Sodium Butyrate, Zinc) Maintenance: BPC-157 and Colostrum can be reduced to 3x/week; Sodium Butyrate and Zinc continue daily Assessment: Symptom tracking + optional biomarkers (zonulin, calprotectin, LPS-binding protein)
Indicators to Track
Subjective: bloating, stool consistency (Bristol scale), post-meal discomfort, energy levels. Objective: zonulin (leaky gut marker), hs-CRP, food sensitivity panel at 12 weeks.
Supporting Interventions
- Eliminate gut irritants: NSAIDs, alcohol, refined sugars during protocol
- Prebiotic/probiotic support: Akkermansia muciniphila, Lactobacillus rhamnosus GG
- L-glutamine 5g/day: additional mucosal substrate
- Zinc carnosine 75mg/day: synergistic gut barrier support
Disclaimer
BPC-157 and KPV are research peptides not approved by the FDA or EMA. This protocol is for educational purposes only.